Market open
$
27.95
Change
+0.11 +0.40%
Volume
Volume 464,201
Oct 4, 2023, 1:23 p.m.
Real time quotes
Previous close
$ 27.84
$ 27.95
Change
+0.11 +0.40%
Day low
Day high
$27.66
$28.21

52 week low
52 week high
$21.75
$33.71

Market cap
$4.64B
Average volume
1.85M
P/E ratio
49.36
Rev. per Employee
$641,238
EPS
0.57
Dividend
N/A
Div yield
N/A
Ex dividend date
N/A
MarketWatch News on ALKS
-
Sleep Number, Newell Brands See Activist Action
- Barron's Online
-
Alkermes, Cogent Biosciences See Activist Action
- Barron's Online
-
Alkermes, Allakos See Activist Action
- Barron's Online
-
Alkermes upgraded to neutral from underperform at BofA Securities
- Tomi Kilgore
-
How to Avoid the Biotech Bear Market: Get Some Products Approved
- Barron's Online
-
Biotech Stocks Are Having a Terrible Year. These 10 Are Still Winning.
- Barron's Online
-
Nektar Shares Halve on Cancer Trial Failure
- Barron's Online
-
Alkermes downgraded to underperform from neutral at BofA Securities
- Tomi Kilgore
-
Alkermes stock halted for news pending
- Tomi Kilgore
-
Biotech Is Down. How It Could Come Back.
- Barron's Online
-
The Case for AbbVie as a Top Biopharma Stock in 2021
- Barron's Online
-
Alkermes upgraded to buy from neutral at Mizuho
- Tomi Kilgore
-
Alkermes stock price target raised to $24 from $19 at Mizuho
- Tomi Kilgore
-
Alkermes downgraded to neutral from buy at BofA Securities
- Tomi Kilgore
-
Alkermes stock price target cut to $20 from $31 at BofA Securities
- Tomi Kilgore
-
Alkermes downgraded to neutral from overweight at J.P. Morgan
- Tomi Kilgore
-
Alkermes stock price target cut to $21 from $25 at J.P. Morgan
- Tomi Kilgore
- Loading more headlines...
Analyst Ratings
-
Benzinga's Top Upgrades, Downgrades For February 22, 2018
- Benzinga.com
-
Your Cheat Sheet For Q1 Biotech Earnings
- Benzinga.com
Other News on ALKS
-
Biogen’s New Boss Is Delivering, but Stock Isn’t Pricing It in Yet
- The Wall Street Journal Interactive Edition
-
- Edgar Online - (EDG = 10Q, 10K)
-
- Edgar Online - (EDG = 10Q, 10K)
-
Can Drugs Treat Addiction? Prisons Offer an Answer
- The Wall Street Journal Interactive Edition
-
Top 5 3rd Quarter Trades of Meditor Group Ltd
- GuruFocus.com
-
Alkermes plc (ALKS) Q3 2022 Earnings Call Transcript
- Seeking Alpha
-
- Edgar Online - (EDG = 10Q, 10K)
-
Alkermes (ALKS) Q3 Earnings Match Estimates
- Zacks.com
-
EMERALD ADVISERS, LLC Buys 1, Sells 4 in 3rd Quarter
- GuruFocus.com
Press Releases on ALKS
-
Alkermes plc Reports First Quarter 2023 Financial Results
- PR Newswire - PRF
-
Alkermes Announces Second Interim Award in Janssen Pharmaceutica Arbitration
- PR Newswire - PRF
-
Alkermes to Report First Quarter Financial Results on April 26, 2023
- PR Newswire - PRF
-
Alkermes to Participate in the Stifel 2023 CNS Days
- PR Newswire - PRF
-
Alkermes to Present at the 41st Annual J.P. Morgan Healthcare Conference
- PR Newswire - PRF
-
Alkermes to Participate in the BofA Securities 2022 Biotech SMID Cap Conference
- PR Newswire - PRF
-
Alkermes to Participate in the 5th Annual Evercore ISI HealthCONx Conference
- PR Newswire - PRF
-
Alkermes to Participate in the Stifel Healthcare Conference
- PR Newswire - PRF
-
Alkermes plc Reports Third Quarter 2022 Financial Results
- PR Newswire - PRF
-
Alkermes plc Announces Intent to Separate Oncology Business
- PR Newswire - PRF
-
Alkermes Announces Recipients of 2022 Alkermes Inspiration Grants(R) Program
- PR Newswire - PRF
- Loading more headlines...
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com